Substituted pyrazoles as p38 kinase inhibitors

US6525059B1 · kind B1 · utility

Assignee

• G.D. Searle LLC · US

Inventors

• Ashok Anantanarayan · Hainesville, US
• Michael Clare · Skokie, US
• Paul W. Collins · Deerfield, US
• Joyce Z. Crich · Glenview, US
• Rajesh Devraj · Chesterfield, US
• Daniel L. Flynn · Lawrence, US
• Lifeng Geng · Skokie, US
• Matthew J. Graneto · Chesterfield, US
• Cathleen Hanau · Chesterfield, US
• Gunnar J. Hanson · Cambridge, US
• Susan J. Hartmann · Kirkwood, US
• Michael Hepperle · Boston, US
• He Huang · Northbrook, US
• Francis J. Koszyk · Prospect Heights, US
• Shuyuan Liao · Northbrook, US
• Suzanne Metz · Chesterfield, US
• Richard A. Partis · Evanston, US
• Thao Perry · San Jose, US
• Shashidhar N. Rao · Chesterfield, US
• Shaun Raj Selness · Chesterfield, US
• Michael S. South · Chesterfield, US
• Michael A. Stealey · Libertyville, US
• John J. Talley · Chesterfield, US
• Michael L. Vazquez · Saint Louis, US
• Richard M. Weier · Lake Bluff, US
• Xiangdong Xu · Gurnee, US
• Ish Khanna · Vernon Hills, US
• Yi Yu · Skokie, US

Key dates

• Filing date: Feb 24, 2000
• Grant date: Feb 25, 2003
• Expiry date: Feb 24, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R 2, R3 and R4 are as described in the specification.